Management of long-term sickness and incapacity: consultation on the evidence (14th May 2008)
NICE was asked by the Department of Health (DH) to develop guidance on the management of long term sickness and incapacity. The aim of this consultation is to enable stakeholders to consider the evidence gathered and to provide the opportunity to comment, in particular on: major gaps in the evidence gathered, including papers in the published literature that we have not been able to identify; queries around the interpretation of the evidence, both of single studies and the reviewed material as a whole; the applicability of the evidence and its usefulness for the development of guidance; issues relating to cost-effectiveness. Closing date for comments is 12th June 2008.
Click here for the Consultation
Influenza (prophylaxis) – amantidine, oseltamivir and zanamivir: appraisal consultation document (16th May 2008)
The Department of Health and the Welsh Assembly Government have asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a multiple technology appraisal of oseltamivir, amantadine and zanamivir and provide guidance on their use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of oseltamivir, amantadine and zanamivir. Closing date for comments is 9th June 2008.
Click here for the Consultation
NICE was asked by the Department of Health (DH) to develop guidance on the management of long term sickness and incapacity. The aim of this consultation is to enable stakeholders to consider the evidence gathered and to provide the opportunity to comment, in particular on: major gaps in the evidence gathered, including papers in the published literature that we have not been able to identify; queries around the interpretation of the evidence, both of single studies and the reviewed material as a whole; the applicability of the evidence and its usefulness for the development of guidance; issues relating to cost-effectiveness. Closing date for comments is 12th June 2008.
Click here for the Consultation
Influenza (prophylaxis) – amantidine, oseltamivir and zanamivir: appraisal consultation document (16th May 2008)
The Department of Health and the Welsh Assembly Government have asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a multiple technology appraisal of oseltamivir, amantadine and zanamivir and provide guidance on their use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of oseltamivir, amantadine and zanamivir. Closing date for comments is 9th June 2008.
Click here for the Consultation
No comments:
Post a Comment